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Abstract — Aims: Physicians recovering from substance-related disorders are usually allowed to return to practice if they agree to
remain abstinent from drugs, including alcohol, and to undergo random urine testing. Over 9000 physicians are currently involved in
such monitoring programs in the US. To date, it has been difficult to adequately monitor abstinence from alcohol due to the short half-
life of alcohol and no other highly specific marker. Ethyl glucuronide (EtG), a direct metabolite of alcohol, offers an extended window
for assessment of drinking status (up to 5 days). Our aim was to assess the potential value of EtG testing in abstinence-based monitoring
programs. Patients and methods: Urine samples were obtained from 100 participants in a physician monitoring program and
additional samples were subsequently obtained ‘for cause’, ‘to verify positive urine alcohol, when drinking was denied’ and ‘in high
risk individuals’. All participants had signed contracts agreeing to remain abstinent from mood-altering drugs, including alcohol, and
had agreed to random urine testing. EtG was determined using LC/MS-MS in addition to standard testing. The main outcome measure
were urine specimens positive for EtG versus those positive based on standard testing for alcohol and other drugs. Results: Among the
initial 100 random samples collected, no sample was positive for alcohol using standard testing; however, seven were positive for EtG
(0.5–196 mg/l), suggesting recent alcohol use. Subsequent EtG testing was performed clinically during the course of monitoring. Of
the 18 tests performed to date, eight of eight tests performed ‘for cause’ were positive for EtG but negative for all other drugs including
urine alcohol. All eight were confirmed positive by self reported drinking by the patient when confronted regarding the positive test
result. Of six tests performed to ‘confirm a positive urine alcohol’ two were positive for EtG and confirmed positive by self reported
drinking. For the other four samples, especially as two are from a diabetic, in vitro fermentation of ethanol is discussed. Conclusions:
These data suggest that physicians in monitoring programs have a higher rate of unrecognized alcohol use than previously reported.
Incorporation of EtG testing into alcohol abstinence monitoring can strengthen these programs.
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Substance abuse by medical practitioners is, by its very nature,
a sensitive, but critical issue. The issue recently achieved news
headline status following an outbreak of bloodstream
infections transmitted by an addicted health professional in an
intensive care unit (Ostrowsky et al., 2002; Verghese, 2002).
Reports have shown that substance-related disorders are as
common among health professionals as, indeed, they are
among the general population with a 10–15% lifetime
prevalence (Brewster, 1986; Talbott, 1987; Anthony, 1992;
Flaherty and Richman, 1993). Reports have shown that with
treatment and long-term monitoring, the prognosis is excellent
with >90% of health professionals with previous substance
abuse disorders remaining abstinent at 5 years follow-up
(Shore, 1987; Skipper, 1997), and that the public is protected.
An unpublished online survey of state Physician Health
Programs revealed a total of 9139 physicians in monitoring
programs in the USA. Similar programs exist for monitoring
other professionals such as attorneys, pilots, etc.
Regulatory boards are charged with overseeing and
regulating licensees and, in turn, support and sanction
Physician Health Programs to accomplish the tasks of early
detection, confidential investigation and intervention, referral
for evaluation and treatment, and monitoring. Relapse rates
amongst physicians participating in Physician Health
Programs have been remarkably low, 1–3% per year (Shore,
1987; Alabama Physician Health Program Annual Report,
2003), a level that has been attributed to intensive long-term
monitoring (Crowley, 1986). An alternative explanation for
the reported low relapse rate might be associated with under-
recognition by those monitoring the patients due to lack of
availability of adequate objective tests.
Additionally, the previously reported high rate of suicide
among physicians disciplined for substance-related disorders
reported by Crawshaw (1980) has markedly decreased.
Certainly other problems cause impairment (e.g. other mental
illness, ageing, etc.) and many are remedial; however
substance-related disorders are the most common and most
treatable.
Monitoring in this population generally includes personal
follow-up, worksite monitor reports, support-group
attendance, and most importantly, random urine testing.
Subject to full chain of custody procedures and sound
methodology, the reliability of urine testing is high and few
false-positive reports occur when positive screening tests are
routinely confirmed by GC/MS or other confirmatory testing.
Urine testing in general has become more prevalent across US
worksites due to emergence of federally mandated drug
testing programs. Millions of urine drug tests are now
performed annually in the US.
More extensive lab test panels are utilized to monitor health
professionals to detect the wider array of drugs available to and
abused by this population. A ‘health professional’ panel
typically includes the top 20–30 prescription drugs, and
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alcohol, most often abused by physicians. Many of the drugs
that are popular among health professionals, including
hydrocodone, oxycodone, meperidine, various benzodi-
azepines and stimulants (such as ritanserin), are reasonably
well detected if tested for because of their long time-frame of
detection in urine. Others, including fentanyl and ethanol, have
relatively short half-lives and are difficult to detect. Fentanyl
can be detected by hair testing, which can be obtained
periodically. Ethanol however, the most common drug of
choice among chemically dependent health professionals, e.g.
44% in Alabama (Alabama Physician Health Program Annual
Report, 2003), is the least amenable to detection. More
accurate testing for alcohol consumption is clearly needed.
The traditional state markers of alcohol consumption such as
gamma-glutamyl-transpeptidase, mean corpuscular volume
and carbohydrate deficient transferrin, reflect chronic
consumption of higher amounts of alcohol and are, therefore,
insensitive indicators of single or short term use. Furthermore,
many currently used state markers are influenced by age,
gender and a variety of substances and non-alcohol-associated
diseases (Gilg and Soyka, 1997; Laposata, 1999). Urine
alcohol is the most commonly used marker for routine
monitoring of health professionals. However, because alcohol
is rapidly metabolized over hours it is a relatively insensitive
test to detect alcohol use. Additionally, because alcohol can be
present in urine because of in vitro fermentation, false-positive
tests for urine alcohol occur (Saady et al., 1993). In contrast,
ethyl glucuronide, EtG, a direct metabolite of ethanol, is only
detected if alcohol is consumed, and remains present in urine
well after the disappearance of ethanol itself. EtG appears to be
a highly sensitive, specific, and reliable marker of recent (up to
5 days) alcohol intake (Kamil et al., 1952; Jaakonmaki et al.,
1967; Kozu, 1973; Schmitt et al., 1995, 1997; Wurst et al.,
1995, 1999a,b, 2000, 2002a,b, 2003a,b; Aderjan et al., 1999;
Nishikawa et al., 1999; Dahl et al., 2002, Goll et al., 2002).
Detection of EtG in urine, therefore, indicates recent alcohol
consumption. Although there is a rough correlation between
the amount of alcohol consumed and the level of EtG detected,
the finding of EtG levels above cut-off values in urine simply
indicates recent alcohol consumption. In this way the results
are binary, indicating the presence of alcohol use, similar to
positive tests for other illicit drugs (i.e. cocaine, opioids, etc.).
The formation of EtG via conjugation of ethanol with
activated glucuronic acid in the presence of membrane-bound
mitochondrial UDP glucuronyl transferase represents ~0.02%
and 0.04% in humans (Dahl et al., 2002; Goll et al., 2002).
The molecular formula of EtG is C8H14O7 and the molecular
weight is 222 g/mol. The melting point (decomposition
temperature) is ~150C. EtG is a non-volatile, water-soluble,
stable marker. Shortly after intake of alcohol, EtG becomes
positive (Wurst et al., 1999, 2002a, 2003b; Dahl et al., 2002)
and is detectable up to 4 days following complete elimination
of alcohol from the body (for review, see Wurst et al., 2003b).
Determination has been reported using GC/MS, LC/MS,
LC/MS-MS and ELISA. More than 4000 samples from more
than 1300 individuals have been tested for EtG by various
research groups, including from the WHO/International
Society for Biomedical Research on Alcoholism (ISBRA)
collaborative study on biological state and trait markers of
alcohol use and dependence. There has been no reported false-
positive test for EtG using LC/MS/MS methods.
The purpose of the current study was to determine if EtG
could identify instances of drinking that failed to be
determined using standard urinanalysis testing for alcohol.
PATIENTS AND METHODS
Patients
Primary screening of 100 subjects. One hundred initial urine
samples were obtained randomly from 100 different healthcare
professionals currently in monitoring. All had diagnoses of
substance dependence and all had completed treatment and
were participants in one of eight physician health programs
from different states. Samples were obtained at a central
laboratory that performs testing for various state programs. All
state physician health programs included operate similarly and
have similar policies, testing procedures, and monitoring
contracts. No other inclusion criteria were applied and there
was no record of participants’ age or sex. Subjects were
presumed to be at varying stages of time following treatment,
as no selection of any subgroup was made. All had signed
monitoring contracts and informed consent agreements
regarding random testing for drugs of abuse, including alcohol.
Investigators were blind to the names of these participants;
therefore exact data regarding individual diagnoses, states from
which the participants came, and how representative these 100
individuals were relative to the more than 9000 individuals in
monitoring in the USA is not known. It is assumed, however,
because they are a random sample, that they are not
appreciably different from others in this group.
Clinical application in 12 physicians. Subsequent to the testing
of the 100 samples above, 18 samples were obtained from a
total of 12 physicians in an operational monitoring setting in
Alabama. Selection for testing was based on one of three
separate indications: i) eight samples were obtained ‘for cause’
(due to reports of suspected drinking), ii) six were obtained ‘to
verify a positive urine alcohol test when drinking was denied’,
and iii) four were obtained randomly in ‘high risk individuals’
with a history of frequent relapses. Data from these tests are
included to demonstrate the early initial evidence of the value
and utility of EtG testing. Use of EtG testing is rapidly
increasing in these programs.
Ethics Committee
IRB review was waived by the Medical Association Ethics
Committee.
Methods
Standard HHS rules were followed for specimen collection and
chain of custody. To avoid risk of substitution or adulteration,
laboratory personnel witnessed all urine test collections. The
limit of determination (LOD) for determination of urinary
alcohol was 0.02 g%. A 3 ml aliquot of each urine sample was
frozen and sent for EtG determination. EtG testing was
performed: i) at the Institute of Legal Medicine, University
of Freiburg, Germany for the first 100 samples, and ii) subse-
quently by a commercial laboratory in the US.
For the EtG LC-MS/MS analysis at the Institute of Legal
Medicine in Germany, a recently published method
(Weinmann et al., 2004) was used with minor modifications.
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The LC-MS/MS system comprised an API 365 triple-
quadrupole mass spectrometer fitted with a turboionspray
interface (Applied Biosystems/Sciex, Langen, Germany) and
coupled to a Shimadzu LC system (two pumps LC10AD
Shimadzu, Duisburg, Germany). Analysis was performed by
multi-reaction monitoring, using 221/75 amu for EtG and
226/75 amu for D5-EtG (dwell times: 400 amu for each
transition), with dummy transitions in between to eliminate
the potential of cross-talk.
The EtG tests on the later 12 physicians performed at a
commercial laboratory in the US, were done using similar
technique as described above.
Other toxicology testing
All specimens, in addition to EtG testing, were analysed at
Quest Diagnostics using an expanded ‘health professionals
panel’. Determination of urinary ethanol was performed as a
screen by the standard enzymatic method using alcohol
dehydrogenase (cut-off: 0.02 g%) and all positive tests were
confirmed by gas chromatography (cut-off: 0.01 g%).
Sample preparation
To 0.2 ml urine sample 10 µl aqueous solution of internal
standard (D5-EtG, 10 µg/ml, Medichem, Germany) and 0.5 ml
methanol were added. After centrifugation (10 min, 14 000
r.p.m. at 4C) the supernatant was evaporated to dryness using a
vacuum concentrator (Christ Alpha RVC, Osterode/ Germany).
Redissolving and dilution was performed in relation to the
creatinine concentration with 0.1% HCOOH (v/v); for
creatinine concentrations <50 mg/dl, the sample was redis-
solved and diluted by factor 2, for creatinine concentrations
50–100 mg/dl by factor 4, for creatinine concentrations
100–200 mg/dl by factor 6, for creatinine concentrations  >200
mg/dl by factor 8. An aliquot of 10 µl of the diluted sample was
injected into the LC/MS/MS system.
Method validation
For the EtG test, method validation has been performed using
a method based on linear regression (Funk et al., 1991) with
an α-error of 1% and a relative confidence interval of 33% 
(k = 3), using B.E.N. software [supplied by Arvecon/
Walldorf, Germany, a standard program for method validation
supported by the German Society of Forensic Toxicologists
(GTFCh) for the detection of drugs of abuse in serum and
urine samples in forensic cases]. The limit of detection of the
method was 0.1 mg/l; the lower limit of quantification
(LLOQ) was 0.3 mg/l.
RESULTS
None of the first 100 specimens were positive for alcohol,
however, seven were positive for ethyl glucuronide at levels of
between 0.5–196 mg/l. Results of EtG positive tests are shown
in Table 1. Creatinine values of between 19.4 and 254.7 mg/dl
were found. EtG/creatinine ratios were utilized to standardize
all EtG values on creatinine 100, resulting in calculated UEtG
100 values and were between 0.2 and 93.8 mg/l.
Of the 18 tests performed so far in the monitoring program
in Alabama, eight were ‘for cause’ due to complaints of
suspected alcohol use, six to ‘confirm positive urine alcohol
tests’ when alcohol use was denied, and four were performed
in individuals routinely due to concern because of frequent
previous relapses (‘high risk’). Among these later tests, eight
of eight tests performed ‘for cause’ were positive for EtG but
negative for all other drugs, including alcohol, and all were
confirmed positive by admission of drinking by the individual
participant, two of six tests performed to ‘confirm a positive
urine alcohol’ were positive and the two tests positive for EtG
were confirmed positive by self reported drinking. None of
the four tests in ‘high risk’ individuals were positive. All
individuals with negative tests reported no ethanol intake (see
Table 2).
DISCUSSION
The role of biological markers in alcoholism treatment has
been recently addressed, with further mention that simply
informing the patient that his or her blood will periodically be
tested to evaluate treatment progress might, in fact, itself
contribute to reducing relapse risk (Allen and Litten, 2001).
Table 1. Synopsis of results for those samples positive for ethyl
glucuronide among the first 100 samples
Sample UEtG Creatinine UEtG 100 Urinary Other drugs
no. [mg/l] [mg/l] [mg/dl] ethanol tested positive
1 42 90.2 46.5 <LOD None
2 1.3 24.9 5.2 <LOD None
3 85 254.7 33.3 <LOD None
4 196 208.8 93.8 <LOD None
5 4.9 19.4 25.3 <LOD None
6 4.1 185 2.2 <LOD None
7 0.5 242.6 0.2 <LOD None
UEtG: urinary ethyl glucuronide; UEtG 100: urinary EtG standardized
for a creatinine of 100 mg/dl; LOD: limit of determination.
Table 2. Synopsis of 18 subsequent EtG tests performed clinically
during monitoring
Confirmed
Reason for UEtG positive by
Patient Age Sex testing mg/l patient
1 50 M For cause 1.2 Yes
2 57 M UAC.01 g% 0 No
3 53 M For cause 2.2 Yes
3 53 M For cause 8.1 Yes
4 46 M For cause 12 Yes
5 55 M High risk 0 No
6 54 M For cause 0.8 Yes
6 54 M For cause 1.6 Yes
7 46 M For cause >100 Yes
7 46 M For cause 0.80 Yes
8 55 M High risk 0 No
8 55 M High risk 0 No
8 55 M High risk 0 No
9 54 M UAC.02 g% 17 Yes
10 36 M UAC.06 g% 2.4 Yes
11 58 M UAC.04 g% 0 No
12 46 M UAC.02 g% 0 No
12 46 M UAC.02 g% 0 No
UAC: Urine alcohol concentration; UEtG: urinary ethyl glucuronide.
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Thus, biomarkers of alcohol use may assist not only in
assessing drinking status but in reducing it.
EtG has been demonstrated to be a useful marker of recent
alcohol consumption because it is a direct metabolite of
alcohol with good sensitivity and specificity and has a
significantly longer time-frame of detection than urine
alcohol. The data presented here suggest that health
professionals in monitoring programs have a higher rate of
alcohol use than previously reported. Among the 100 random
samples reported here, the participants were anonymous and
follow-up interviews to establish specificity were, therefore,
not possible. High specificity has been established elsewhere
(Wurst et al., 2003b). In the subsequent group of 12 patients
selected for testing utilizing EtG clinically it proved very
effective. All positive tests in cases of testing ‘for cause’ were
corroborated by self reported drinking. However, in the six
cases with a positive UAC, only two were positive for EtG and
confirmed by self reported alcohol intake. The other four need
not necessarily be false negative tests for EtG, as a positive
UAC does not necessarily prove an intake of ethanol. Due to
fermentation of glucose, which is excreted by persons
suffering from diabetes (like known for patient number 12,
two samples), a significant rise of the UAC can occur at room
temperature or elevated temperature in the pre-analytical
period, e.g. when samples are not frozen when being delivered
by postal service to the laboratory. In contrast to this
possibility of in vitro formation of ethanol in urine, EtG is not
known to be generated during the fermentation process. We
therefore conclude that the positive results for UAC in patients
2 and 11 and negative results for EtG in the same samples not
necessarily reflect false negatives for EtG but might be
explained — also taking into consideration the negative self
reports — by in vitro ethanol fermentation.
Recent preliminary anecdotal reports from numerous state
physician health programs performing EtG testing suggest
significant benefit: in Florida, for example, of 22 tests
performed, 10 have been positive for EtG and all have been
confirmed to be associated with admitted drinking episodes
(personal communication with staff at the Florida Professional
Recovery Network, 2004). In Alabama — as reported here —
18 EtG tests were performed over the past 6 months and
appear useful as shown above.
Since the introduction of testing capability for EtG by
laboratories in the USA in 2003, it is proving to be a valuable
tool in these programs. The test has also been discussed for
use in school testing programs, with pilots recovering from
alcoholism and others. Because EtG testing is currently being
performed using Liquid Chromatography Tandem Mass
Spectroscopy (LC–MS/MS) the test is relatively expensive (up
to US$70), which limits its use. Development of an ELISA
screening test for EtG is under development and should
greatly reduce the cost. Some monitoring programs are
attempting to include EtG in all urine panels. Others are using
the test selectively, primarily in three settings: i) to confirm
positive urine alcohol tests if alcohol use is denied, ii) ‘for
cause’ when there is a heightened concern (such as following
a report of suspected ‘alcohol on the breath’), and iii)
randomly and more routinely in ‘high risk’ individuals with a
history of multiple relapses.
Questions regarding positive tests due to incidental expo-
sure to alcohol [alcohol in food, over the counter medication
(OTC meds; such as cough syrup), communion wine, mouth-
wash, etc.] are being asked. Because such a small fraction of
consumed alcohol is metabolized to EtG, a significant amount
of alcohol must be consumed for EtG to be detected in urine.
However, cut-off levels for measuring EtG in urine have
been set at between 100–250 g/l to eliminate detection of
incidental minor exposure to alcohol. Additionally, it is
recommended that individuals in abstinence monitoring be
advised and agree to abstain, not only from overt alcohol use,
but also from any alcohol use in food, OTC meds, communion
wine, etc., to avoid claims of false-positive tests. Current
analysis suggests that if the level of EtG in urine exceeds
500 g/l, incidental exposure is extremely unlikely. In any
event, if testing is positive, as with any laboratory test, clinical
correlation is important.
Monitoring health professionals in recovery from
substance-related disorders is necessary and important to
protect patients and maintain high rates of success. By having
reliable accurate testing programs the chances of early
detection and assistance are optimized. Work-related
monitoring with contingency contracting appears to be
effective in reducing the rate of relapse. Use of better markers,
such as the direct ethanol metabolite EtG, can help these
programs maintain credibility and improve outcomes. The
cumulative data suggest that ethyl glucuronide is a promising
marker of recent alcohol use and will become an important
part of the monitoring armamentarium. An ELISA (enzyme
linked immunosorbent assay) screening test for EtG based on
a monoclonal antibody is being developed (Mediagnost Inc.,
Germany) and, when available, will facilitate inclusion in
routine testing panels. That EtG can be detected in various
other body fluids including serum/blood, hair, and in tissue
samples, may make the biomarker quite versatile in other
situations where alcohol use must be determined some time
after its occurrence (for review, see Wurst et al., 2003b).
The complementary use of this marker together with other
biological state markers and self reports in similar settings like
the one described above (e.g. airline pilots, during pregnancy,
workplace testing in safety sensitive jobs, methadone
programs, etc.) is expected to lead to significant improvement
in treatment outcome, therapy effectiveness, and considerable
health, social and socio-economic benefits.
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